Streetbeat News

Analyst Ratings

ASML

Susquehanna analyst Mehdi Hosseini maintains a Positive rating on ASML Holding but lowers the price target from $1300 to $1100.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:15 pm

AMAT

Susquehanna analyst Mehdi Hosseini maintains a Neutral rating on Applied Materials (NASDAQ:AMAT) and lowers the price target from $215 to $190.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:14 pm

AEIS

Susquehanna analyst Mehdi Hosseini maintains a Neutral rating on Advanced Energy Industries (NASDAQ:AEIS) and lowers the price target from $103 to $92.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:13 pm

TLRY

Roth MKM analyst Bill Kirk has maintained a Neutral rating on Tilray Brands (NASDAQ:TLRY) while lowering the price target from $2 to $1.75.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:12 pm

GWRE

Wells Fargo analyst Michael Turrin has maintained an Overweight rating on Guidewire Software and raised the price target from $200 to $205.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:12 pm

META

Roth MKM analyst Rohit Kulkarni has maintained a Buy rating on Meta Platforms and increased the price target from $550 to $620.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:10 pm

MSCI

Wells Fargo analyst Jason Haas has maintained an Equal-Weight rating on MSCI and increased the price target from $570 to $600.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:10 pm

SAIC

Wells Fargo analyst Matthew Akers has maintained an Equal-Weight rating on Science Applications International Corp (SAIC) and raised the price target from $122 to $157.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:08 pm

ADMA

AMT

CVS

HOOD

HWM

MOD

MU

Jim Cramer discussed several stocks on CNBC's 'Mad Money Lightning Round.' He sees value in CVS Health, praises Micron Technology's quarter, and recommends buying Robinhood and Modine Manufacturing. He advises against American Tower and considers ADMA Biologics speculative.

Portfolio Pulse from Avi Kapoor

October 11, 2024 | 1:06 pm

ACCD

Wells Fargo analyst Stan Berenshteyn has maintained an Equal-Weight rating on Accolade (NASDAQ:ACCD) but has lowered the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 1:04 pm